We are excited to learn Ferrer has advanced their research into PSP with a phase 2 clinical trial called PROSPER. Phase 2 trials are held to help assess how a drug interacts with our body, it’s efficacy and most importantly safety.
Ferrer are testing an enzyme inhibitor called FNP-223 which aims to slow progression of PSP as a disease modifying treatment. It is hoped FNP-223 will help stop the enzyme from working, preventing the creation of the toxic tau and slow progression of the disease. They hope to recruit 220 participants across the USA, UK and the EU. PROSPER is currently only recruiting in the United States.
PSPA have been supporting Ferrer through our PRIM group and we look forward to hearing how the trial progresses.
Read the research announcement in full on Ferrer’s website.
If you would like to sign up to PSPA’s Research Register, so you can help support research studies and trials in the future.
